Stifel Nicolaus lifted their price target on shares of Newlink Genetics Cor (NASDAQ: NLNK) from $16.00 to $19.00 in a research note issued on Friday. The firm currently has a “buy” rating on the stock.
Separately, analysts at Robert W. Baird reiterated an “outperform” rating on shares of Newlink Genetics Cor in a research note to investors on Friday, March 30th.
Newlink Genetics Cor opened at 12.00 on Friday. Newlink Genetics Cor has a 1-year low of $6.25 and a 1-year high of $12.37. The company’s market cap is $248.1 million.
NewLink Genetics Corporation (NewLink) is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment.